Multiple Myeloma
17 videos · last 6 months shuffled daily, then older videos newest first
▶
6:20 MONVISO: Etentamig Efficacy by Prior BCMA Therapy
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona describes how efficacy of etentamig, a BCMA x CD3 bispecific, varied by prior BCMA-targeting therapy in the phase 1b MONVISO study presented at ASCO 2026, for Blood Cancers Today.
▶
1:26 Iberdomide FDA Approval and the Next CELMoDs in Myeloma
Sagar Lonial, MD, discusses the FDA approval of iberdomide for multiple myeloma and the CELMoD trials to watch next, including mezigdomide in the phase 3 SUCCESSOR-2 trial, at the 2026 International Myeloma Society meeting, for Targeted Oncology.
▶
8:32 MONVISO: Etentamig Safety in Relapsed Multiple Myeloma
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona discusses safety results from the phase 1b MONVISO study of etentamig, a BCMA x CD3 bispecific, in relapsed or refractory multiple myeloma, for Blood Cancers Today.
▶
1:05 Teclistamab in Previously Treated Multiple Myeloma (MajesTEC-9)
In the Phase 3 MajesTEC-9 trial, teclistamab improved 18-month progression-free survival in relapsed multiple myeloma against standard therapy. Grade 3 or 4 infections were common.
▶
3:54 Blood Cancers Today on the SUCCESSOR-2 Trial in Multiple Myeloma
Dr. Paul Richardson of Dana-Farber on SUCCESSOR-2, a phase 3 trial comparing mezigdomide-carfilzomib-dexamethasone with carfilzomib-dexamethasone in refractory multiple myeloma, presented at ASCO 2026.
▶
18:54 OTEOB From ASCO 2026: What’s Changing in Prostate, Lung and Multiple Myeloma Research
Monty Pal, M.D., talks with Alan Bryce, M.D., Kristin Higgins, M.D., and Joseph Mikhael, M.D., of City of Hope about the prostate, lung and multiple myeloma research shaping conversations at ASCO 2026.
▶
1:48 Saad Usmani, MD, Discusses Iberdomide Approval in Relapsed Multiple Myeloma
Dr. Saad Usmani of Memorial Sloan Kettering Cancer Center discusses the FDA approval of iberdomide plus dexamethasone in relapsed multiple myeloma, based on the SUCCESSOR-2 trial.
▶
6:55 LINKER-SMM1 Assesses Linvoseltamab for High-Risk Smoldering Multiple Myeloma
Paula Rodríguez-Otero, MD, PhD, of the University of Navarra, lead author of the phase 2 LINKER-SMM1 trial, discusses safety and efficacy results for linvoseltamab in high-risk smoldering multiple myeloma, including a May 2026 update, for Blood Cancers Today.
▶
9:32 IRAKLIA: Isatuximab Results by Prior Anti-CD38 Therapy
Sikander Ailawadhi, MD, of the Mayo Clinic Comprehensive Cancer Center discusses a post hoc analysis of the phase 3 IRAKLIA trial of isatuximab with pomalidomide and dexamethasone by prior anti-CD38 therapy, presented at ASCO 2026, for Blood Cancers Today.
▶
2:46 ASCO 2026: CARTITUDE-4 Cytogenetic Subgroup Analysis
Roberto Mina, MD, of Winship Cancer Institute at Emory discusses the CARTITUDE-4 cytogenetic subgroup analysis in relapsed or refractory multiple myeloma.
▶
4:52 A Young Hematologic Oncologist's Research Career
Luis Malpica Castillo, MD, of the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, describes how his clinical research interests began in infectious disease and HTLV-1 and led him to lymphoma, for Blood Cancers Today.
▶
10:29 MonumenTAL-6 Results in Relapsed/Refractory Myeloma
Ajay K. Nooka, MD, MPH, of Emory University School of Medicine discusses topline results from the phase 3 MonumenTAL-6 trial of teclistamab plus talquetamab, or talquetamab plus pomalidomide, in relapsed/refractory multiple myeloma, for CheckRare.
▶
3:40 ASCO 2026: MajesTEC-9 Clinical Trial Results
Roberto Mina, MD, of Winship Cancer Institute at Emory discusses results from the MajesTEC-9 trial in relapsed or refractory multiple myeloma.
▶
6:53 IBEX Study: Iberdomide Plus Daratumumab Myeloma Maintenance
Jeffrey Zonder, MD, of Karmanos Cancer Institute discusses first results from the IBEX study of iberdomide plus subcutaneous daratumumab as maintenance after stem cell transplant, including side effects and MRD responses, at IMS 2026.
▶
58:30 Myeloma Data from ASCO and EHA: Patient FAQs
Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center and Amrita Krishnan, MD, of City of Hope answer frequently asked questions about multiple myeloma data presented at the ASCO and EHA meetings in 2026, for the MMRF.
▶
2:19 OPTIMUM/MUKnine: Genetic Risk in Ultra-High-Risk Myeloma
Martin Kaiser, MD, of The Royal Marsden discusses an exploratory genetic analysis from the Phase II OPTIMUM/MUKnine trial in ultra-high-risk newly diagnosed multiple myeloma, at the International Myeloma Society 2026 meeting.
▶
51:01 Legend Biotech's Alan Bash on Commercializing CAR-T
Alan Bash, President, Carvykti, at Legend Biotech, discusses how Carvykti became a leading CAR-T therapy for multiple myeloma, commercial-scale manufacturing, the Johnson & Johnson partnership and new competitors, on Life Science Connect's Business of Biotech.